From the Journals

Adjuvant Everolimus Offers No Survival Benefit in Non–Clear Cell RCC


 

SOURCE:

The study was led by Shuchi Gulati, MD, MSc, University of California Davis Comprehensive Cancer Center, Sacramento, and was published online on August 6, 2024, in JAMA Network Open, along with an accompanying editorial.

LIMITATIONS:

The subgroup analyses were underpowered to detect a significant difference. Additionally, the study lacked a central pathology review to confirm non–clear cell histologies.

DISCLOSURES:

The study was supported by awards from the National Institutes of Health, National Cancer Institute, and National Clinical Trials Network. Several authors reported receiving grants or personal fees from various sources outside the submitted work.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Artera Launches AI Test for Decision-Making on Prostate Cancer Treatment Course
MDedge Hematology and Oncology
Can Addressing Depression Reduce Chemo Toxicity in Older Adults?
MDedge Hematology and Oncology
Immunotherapy May Be Overused in Dying Patients With Cancer
MDedge Hematology and Oncology
BRCA Mutations in Men: Important but Often Overlooked
MDedge Hematology and Oncology
Few Severe Toxicities After SBRT in Oligometastatic Cancer
MDedge Hematology and Oncology
When Childhood Cancer Survivors Face Sexual Challenges
MDedge Hematology and Oncology
Can Belzutifan Improve Outcomes in Advanced RCC?
MDedge Hematology and Oncology
Cancer Treatment 101: A Primer for Non-Oncologists
MDedge Hematology and Oncology
Could Baseline MRIs Reshape Prostate Cancer Risk Assessment?
MDedge Hematology and Oncology
Cancer Cases, Deaths in Men Predicted to Surge by 2050
MDedge Hematology and Oncology